A systematic review of drugs in late-stage development for the treatment of multiple sclerosis: A focus on oral synthetic drugs

Inflammation and Allergy - Drug Targets

Volumn 13, Issue 6, 2015, Pages 351-366

  Safavi, Malihe ^a   Nikfar, Shekoufeh ^b   Abdollahi, Mohammad ^c  

^a IRANIAN RESEARCH ORGANIZATION FOR SCIENCE AND TECHNOLOGY IROST   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trials; Laquinimod; Masitinib; Multiple sclerosis; Siponimod; Systematic review

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; FIBRINOGEN; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; MASITINIB; MITOXANTRONE; NATALIZUMAB; PEGINTERFERON BETA1A; PLACEBO; ROQUINIMEX; SIPONIMOD; TERIFLUNOMIDE; IMMUNOLOGIC FACTOR; MOLECULAR LIBRARY; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRADYCARDIA; BUDD CHIARI SYNDROME; COUGHING; DIARRHEA; DISABILITY; DIZZINESS; DRUG DESIGN; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; LEIOMYOMA; MENOMETRORRHAGIA; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PUBLICATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE RISK; RHINOPHARYNGITIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THORAX PAIN; UTERUS BLEEDING; META ANALYSIS; MOLECULAR LIBRARY;

HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; QUINOLONES; SMALL MOLECULE LIBRARIES; THIAZOLES;

EID: 84934756877     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528114666150529102613     Document Type: Article

References (119)

1. Nikfar, S.; Rahimi, R.; Abdollahi, M. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type. Clin. Therap., 2010, 32, 1871-1888.
2. Nikfar, S.; Rahimi, R.; Abdollahi, M. A systematic review on the efficacy of interferon beta in relapsing remitting multiple sclerosis; Comparison of different formulations. Int. J. Pharmacol., 2010, 6, 638-644.
3. Nikfar, S.; Rahimi, R.; Rezaie, A.; Abdollahi, M. A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis. Arch. Med. Sci., 2010, 6, 236-344.
4. Nikfar, S.; Kebriaeezadeh, A.; Dinarvand, R.; Abdollahi, M.; Sahraian, M. A.; Henry, D.; Akbari Sari, A. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. Daru, 2013, 21, 50.
5. Mokarizadeh, A.; Abdollahi, M.; Rezvanfar, M. A.; Rahmani, M. R. The possible role of peripherally generated cross-reactive IgG in break-down of the blood-brain barrier and initiation of multiple sclerosis. J. Med. Hypotheses. Ideas., 2014, 8, 63-68.
6. Lublin, F. D.; Reingold, S. C.; Cohen, J. A.; Cutter, G. R.; Sorensen, P. S.; Thompson, A. J.; Wolinsky, J. S.; Balcer, L. J.; Banwell, B.; Barkhof, F.; Bebo, B. Jr.; Calabresi, P. A.; Clanet, M.; Comi, G.; Fox, R. J.; Freedman, M. S.; Goodman, A. D.; Inglese, M.; Kappos, L.; Kieseier, B. C.; Lincoln, J. A.; Lubetzki, C.; Miller, A. E.; Montalban, X.; O'Connor, P. W.; Petkau, J.; Pozzilli, C.; Rudick, R. A.; Sormani, M. P.; Stuve, O.; Waubant, E.; Polman, C. H. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, 2014, 83, 278-286.
7. Tullman, M. J. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am. J. Manag. Care, 2013, 19, S15-S20.
8. Castro-Borrero, W.; Graves, D.; Frohman, T. C.; Flores, A. B.; Hardeman, P.; Logan, D.; Orchard, M.; Greenberg, B.; Frohman, E. M. Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord., 2012, 5, 205-220.
9. Disanto, G.; Berlanga, A. J.; Handel, A. E.; Para, A. E.; Burrell, A. M.; Fries, A.; Handunnetthi, L.; De Luca, G. C.; Morahan, J. M. Heterogeneity in multiple sclerosis: scratching the surface of a complex disease. Autoimmune Dis., 2010, 2011, 932351-932363.
10. Bruck, W.; Wegner, C. Insight into the mechanism of laquinimod action. J. Neurol. Sci., 2011, 306, 173-179.
11. Kieseier, B. C. The mechanism of action of interferon-β in relapsing multiple sclerosis. Clin. Rheumatol., 2008, 27, 1467-1468.
12. Zajicek, J. Diagnosis and disease modifying treatments in multiple sclerosis. Postgrad. Med. J., 2005, 81, 556-561.
13. Dutta, R.; Trapp, B. D. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog. Neurobiol., 2011, 93, 1-12.
14. Trapp, B. D.; Nave, K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci., 2008, 31, 247-269.
15. Hauser, S. L.; Oksenberg, J. R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron, 2006, 52, 61-76.
16. Palmer, A. M. Pharmacotherapeuetic options for the treatment of multiple sclerosis. Clinical Medicine Insights: Therapeutics, 2012, 4, 145-168.
17. Bol, Y.; Smolders, J.; Duits, A.; Lange, I. M.; Romberg-Camps, M.; Hupperts, R. Fatigue and heat sensitivity in patients with multiple sclerosis. Acta. Neurol. Scand., 2012, 126, 384-389.
18. Polman, C. H.; Uitdehaag, B. M. J. Drug treatment of multiple sclerosis. West J. Med., 2000, 173, 398-402.
19. Varrin-Doyer, M.; Zamvil, S. S.; Schulze-Topphoff, U. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp. Neurol., 2014, 262PA, 66-71.
20. Tanasescu, R.; Ionete, C.; Chou, I-J.; Constantinescu, C. S. Advances in the treatment of relapsing-remitting multiple sclerosis. Biomed. J., 2014, 37, 41-49.
21. Kieseier, B. C.; Wiendl, H.; Hartung, H-P.; Stuve, O. The future of multiple sclerosis therapy. Pharmacol. Res., 2009, 60, 207-211.
22. Aharoni, R.; Saada, R.; Eilam, R.; Hayardeny, L.; Sela, M.; Arnon, R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2012, 251, 14-24.
23. Jonsson, S.; Andersson, G.; Fex, T.; Fristedt, T.; Hedlund, G.; Jansson, K.; Abramo, L.; Fritzson, I.; Pekarski, O.; Runstrom, A.; Sandin, H.; Thuvesson, I.; Bjork, A. Synthesis and Biological Evaluation of New 1, 2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure-Activity Relationship. J. Med. Chem., 2004, 47, 2075-2088.
24. Ruffini, F.; Rossi, S.; Bergamaschi, A.; Brambilla, E.; Finardi, A.; Motta, C.; Studer, V.; Barbieri, F.; De Chiara, V.; Hayardeny, L.; Comi, G.; Centonze, D.; Martino, G. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult. Scler., 2013, 19, 1084-1094.
25. Toubi, E.; Nussbaum, S.; Staun-Ram, E.; Snir, A.; Melamed, D.; Hayardeny, L.; Miller, A. Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J. Neuroimmunol., 2012, 251, 45-54.
26. Yang, J. S.; Xu, L. Y.; Xiao, B. G.; Hedlund, G.; Link, H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J. Neuroimmunol., 2004, 156, 3-9.
27. Brunmark, C.; Runstro, A.; Ohlsson, L.; Sparre, B.; Brodin, T.; Astrom, M.; Hedlund, G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2002, 130, 163-172.
28. Mishra, M. K.; Wang, J.; Silva, C.; Mack, M.; Yong, V. W. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am. J. Pathol., 2012, 181, 642-651.
29. Jolivel, V.; Luessi, F.; Masri, J.; Kraus, S. H.; Hubo, M.; Poisa-Beiro, L.; Klebow, S.; Paterka, M.; Yogev, N.; Tumani, H.; Furlan, R.; Siffrin, V.; Jonuleit, H.; Zipp, F.; Waisman, A. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain, 2013, 136, 1048-1066.
30. Schulze-Topphoff, U.; Shetty, A.; Varrin-Doyer, M.; Molnarfi, N.; Sagan, S. A.; Sobel, R. A.; Nelson, P. A.; Zamvil, S. S. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One, 2012, 7, 33797-33807.
31. Zou, L. P.; Abbas, N.; Volkmann, I.; Nennesmo, I.; Levi, M.; Wahren, B.; Winblad, B.; Hedlund, G.; Zhu, J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology, 2002, 42, 731-739.
32. Wegner, C.; Stadelmann, C.; Pfortner, R.; Raymond, E.; Feigelson, S.; Alon, R.; Timan, B.; Hayardeny, L.; Bruck, W. Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2010, 227, 133-143.
33. Gurevich, M.; Gritzman, T.; Orbach, R.; Raymond, E.; Feigelson, S.; Alon, R.; Timan, B.; Hayardeny, L.; Bruck, W. Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study. J. Neuroimmunol., 2010, 221, 87-94.
34. Tiwari-Woodruff, S.; Yoon, J.; Khalaj, A.; Ichwan, D.; McLauglin, T.; Patel, R. Laquinimod treatment reverses cortical and hippocampus pathology due to inflammatory demyelination in a chronic mouse model of multiple sclerosis. Neurology, 2013, 80, (Poster P06. 126).
35. Thone, J.; Ellrichmann, G.; Seubert, S.; Peruga, I.; Lee, D. H.; Conrad, R.; Hayardeny, L.; Comi, G.; Wiese, S.; Linker, R. A.; Gold, R. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am. J. Pathol., 2012, 180, 267-274.
36. Bruck, W.; Zamvil, S. S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. Expert Rev. Clin. Pharmacol., 2012, 5, 245-256.
37. Mishra, M. K.; Wang, J.; Keough, M. B.; Fan, Y.; Silva, C.; Sloka, S.; Hayardeny, L.; Bruck, W.; Yong, V. W. Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann. Clin. Transl. Neurol., 2014, 1, 409-422.
38. Moore, S.; Khalaj, A. J.; Yoon, J.; Patel, R.; Hannsun, G.; Yoo, T.; Sasidhar, M.; Martinez-Torres, L.; Hayardeny, L.; Tiwari-Woodruff, S. K. Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav., 2013, 3, 664-682.
39. Tuvesson, H.; Hallin, I.; Persson, R.; Sparre, B.; Gunnarsson, P. O.; Seidegard, J. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab. Dispos., 2005, 33, 866-872.
40. Tuvesson, H.; Hallin, I.; Ellman, M.; Sparre, B.; Gunnarsson, P. O.; Seidegard, J. In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species. Xenobiotica, 2005, 35, 293-304.
41. Runstrom, A.; Leanderson, T.; Ohlsson, L.; Axelsson, B. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k. o. and wild type mice. J. Neuroimmunol., 2006, 173, 69-78.
42. Polman, C.; Barkhof, F.; Sandberg-Wollheim, M.; Linde, A.; Nordle, O.; Nederman, T. Laquinimod in Relapsing MS Study Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology, 2005, 64, 987-991.
43. Lund, B. T.; Kelland, E. E.; Hayardeny, L.; Barilan, O.; Gilmore, W.; Weiner, L. P. Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod. J. Neuroimmunol., 2013, 263, 108-115.
44. Hallak, H.; Tarcic, N.; Kaye, F. Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Fingolimod. 2013; US 20130096158 A1.
45. Comi, G.; Pulizzi, A.; Rovaris, M.; Abramsky, O.; Arbizu, T.; Boiko, A.; Gold, R.; Havrdova, E.; Komoly, S.; Selmaj, K.; Sharrack, B.; Filippi, M. LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 2008, 371, 2085-2092.
46. Comi, G.; Abramsky, O.; Arbizu, T.; Boyko, A.; Gold, R.; Havrdova, E.; Komoly, S.; Selmaj, K.; Sharrack, B.; Filippi, M.; LAQ/5063 Study Group. Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallelgroup placebo-controlled study. Mult. Scler., 2010, 16, 1360-1366.
47. A service of the U. S. National Institutes of Health. An open label extension of the LAQ/5062 and LAQ/5063 studies to assess the long term safety and tolerability of laquinimod 0. 6mg in RRMS patients 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT00745615 (Last accessed January 12, 2015).
48. A service of the U. S. National Institutes of Health. A phase 2 clinical study in subjects with primary progressive multiple sclerosis to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0. 6 mg/day or 1. 5mg/day (experimental drug) as compared to placebo. 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT02284568 (Last accessed January 12, 2015).
49. Comi, G.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A.; Rocca, M. A.; Filippi, M.; ALLEGRO Study Group. Placebocontrolled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med., 2012, 366, 1000-1009.
50. Comi, G.; Jeffery, D.; Kappos, L.; Montalban, A.; Boyko, A.; Rocca, M.; Filippi, M. Comparison of early and delayed oral laquinimod in patients with relapsing-remitting multiple sclerosis: effects on disability progression at 36 months in the ALLEGRO trial. Neurology, 2013, 80, (Poster P41. 004).
51. Filippi, M.; Rocca, M. A.; Pagani, E.; De Stefano, N.; Jeffery, D.; Kappos, L.; Montalban, X.; Boyko, A. N.; Comi, G.; ALLEGRO Study Group. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry, 2014, 85, 851-858.
52. Vollmer, T. L.; Sorensen, P. S.; Selmaj, K.; Zipp, F.; Havrdova, E.; Cohen, J. A.; Sasson, N.; Gilgun-Sherki, Y.; Arnold, D. L.; BRAVO Study Group. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J. Neurol., 2014, 261, 773-783.
53. A service of the U. S. National Institutes of Health. A study to evaluate the long-term safety, tolerability and effect of daily oral laquinimod 0. 6 mg on disease course in subjects with relapsing multiple sclerosis 2015. Available from: URL: https://www. clinicaltrials. gov/ct2/show/NCT01047319 (Last accessed January 12, 2015).
54. A service of the U. S. National Institutes of Health. A study to evaluate the long-term safety, tolerability and effect on disease course 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT00988052 (Last accessed January 12, 2015).
55. A service of the U. S. National Institutes of Health. The efficacy and safety and tolerability of laquinimod in subjects with relapsing remitting multiple sclerosis (RRMS). 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT01707992 (Last accessed January 12, 2015).
56. Dubreuil, P.; Letard, S.; Ciufolini, M.; Gros Gros, L.; Humbert, M.; Casteran, N.; Borge, L.; Hajem, B.; Lermet, A.; Sippl, W.; Voisset, E.; Arock, M.; Auclair, C.; Leventhal, P. S.; Mansfield, C. D.; Moussy, A.; Hermine, O. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE, 2009, 4, 7258-7270.
57. Paul, C.; Sans, B.; Suarez, F.; Casassus, P.; Barete, S.; Lanternier, F.; Grandpeix-Guyodo, C.; Dubreuil, P.; Palmerini, F.; Mansfield, C. D.; Gineste, P.; Moussy, A.; Hermine, O.; Lortholary, O. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am. J. Hematol., 2010, 85, 921-925.
58. Al-Azzam, N.; Kondeti, V.; Duah, E.; Gombedza, F.; Thodeti, C. K.; Paruchuri, S. Modulation of mast cell proliferative and inflammatory responses by leukotriene d4 and stem cell factor signaling interactions. J. Cell Physiol., 2015, 230, 595-602.
59. Moussy, A.; Kinet, J. P. Treatment of multiple sclerosis with masitinib. US 20130202555 A1 (2013).
60. Secor, V. H.; Secor, W. E.; Gutekunst, C. A.; Brown, M. A. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med., 2000, 191, 813-822.
61. Rozniecki, J. J.; Hauser, S. L.; Stein, M.; Lincoln, R.; Theoharides, T. C. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann. Neurol., 1995, 37, 63-66.
62. Theoharides, T. C.; Dimitriadou, V.; Letourneau, R.; Rozniecki, J. J.; Vliagoftis, H.; Boucher, W. Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain myelin changes resembling early stages of demyelination. Neuroscience, 1993, 57, 861-871.
63. Rejdak, K.; Eikelenboom, M. J.; Petzold, A.; Thompson, E. J.; Stelmasiak, Z.; Lazeron, R. H.; Barkhof, F.; Polman, C. H.; Uitdehaag, B. M.; Giovannoni, G. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology, 2004, 63, 1439-1445.
64. Jack, C.; Antel, J.; Bruck, W.; Kuhlmann, T. Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia, 2007, 55, 926-934.
65. Bissonnette, E. Y.; Hogaboam, C. M.; Wallace, J. L.; Befus, A. D. Potentiation of tumor necrosis factor-alpha-mediated cytotoxicity of mast cells by their production of nitric oxide. J. Immunol., 1991, 147, 3060-3065.
66. Bidri, M.; Ktorza, S.; Vouldoukis, I.; Le Goff, L.; Debre, P.; Guillosson, J. J.; Arock, M. Nitric oxide pathway is induced by Fc epsilon RI and up-regulated by stem cell factor in mouse mast cells. Eur. J. Immunol., 1997, 27, 2907-2913.
67. Kocic, I.; Kowianski, P.; Rusiecka, I.; Lietzau, G.; Mansfield, C.; Moussy, A.; Hermine, O.; Dubreuil, P. Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn. Schmiedebergs. Arch. Pharmacol., 2015, 388, 79-86.
68. Humbert, M.; de Blay, F.; Garcia, G.; Prud'homme, A.; Leroyer, C.; Magnan, A.; Tunon-de-Lara, J. M.; Pison, C.; Aubier, M.; Charpin, D.; Vachier, I.; Purohit, A.; Gineste, P.; Bader, T.; Moussy, A.; Hermine, O.; Chanez, P. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy, 2009, 64, 1194-12010.
69. Piette, F.; Belmin, J.; Vincent, H.; Schmidt, N.; Pariel, S.; Verny, M.; Marquis, C.; Mely, J.; Hugonot-Diener, L.; Kinet, J. P.; Dubreuil, P.; Moussy, A.; Hermine, O. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res. Ther., 2011, 3, 16-72.
70. Tebib, J.; Mariette, X.; Bourgeois, P.; Flipo, R. M.; Gaudin, P.; Le Loet, X.; Gineste, P.; Guy, L.; Mansfield, C. D.; Moussy, A.; Dubreuil, P.; Hermine, O.; Sibilia, J. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res. Ther., 2009, 11, 95-107.
71. Vermersch, P.; Benrabah, R.; Schmidt, N.; Zephir, H.; Clavelou, P.; Vongsouthi, C.; Dubreuil, P.; Moussy, A.; Hermine, O. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol., 2012, 12, 36-45.
72. A service of the U. S. National Institutes of Health. A phase 2b/3 study to compare efficacy and safety of masitinib to placebo in the treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT01433497 (Last accessed January 12, 2015).
73. Bigaud, M.; Guerini, D.; Billich, A.; Bassilana, F.; Brinkmann, V. Second generation S1P pathway modulators: research strategies and clinical developments. Biochim. Biophys. Acta., 2014, 1841, 745-758.
74. Brinkmann, V.; Davis, M. D.; Heise, C. E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C. A.; Zollinger, M.; Lynch, K. R. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem., 2002, 277, 21453-21457.
75. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L.; Cyster, J. G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 2004, 427, 355-360.
76. Van Doorn, R.; Van Horssen, J.; Verzijl, D.; Witte, M.; Ronken, E.; Van Het Hof, B.; Lakeman, K.; Dijkstra, C. D.; Van Der Valk, P.; Reijerkerk, A.; Alewijnse, A. E.; Peters, S. L.; De Vries, H. E. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia, 2010, 58, 1465-1476.
77. Oravecz, T.; Donoviel, M. S.; Anderson, S. J.; Carson, K.; Sun, W.; Swaffield, J.; Liu, Q. S.; Kimball, D.; Piggott, J. R.; Main, A. J.; Zambrowicz, B. P.; Sands, A. T.; Turner, C. A.; Augeri, D. J. Genetic and chemical inhibition of sphingosine 1-phosphate lyase results in peripheral lymphopenia and alleviates disease development in animal models of inflammation and autoimmunity. Blood, 2007, 110, (Poster P2292).
78. Sanna, M. G.; Liao, J.; Jo, E.; Alfonso, C.; Ahn, M. Y.; Peterson, M. S.; Webb, B.; Lefebvre, S.; Chun, J.; Gray, N.; Rosen, H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem., 2004, 279, 13839-13848.
79. Kułakowska, A.; Zendzian-Piotrowska, M.; Baranowski, M.; Konończuk, T.; Drozdowski, W.; Gorski, J.; Bucki, R. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci. Lett., 2010, 477, 149-152.
80. Fujii, Y.; Ohtake, H.; Ono, N.; Hara, T.; Sakurai, T.; Takahashi, S.; Takayama, T.; Fukasawa, Y.; Shiozawa, F.; Tsukahara, N.; Hirayama, T.; Igarashi, Y.; Goitsuka, R. Lymphopenia induced by a novel selective S1P(1) antagonist structurally unrelated to S1P. Biochim. Biophys. Acta., 2012, 1821, 600-606.
81. Angst, D.; Janser, P.; Quancard, J.; Buehlmayer, P.; Berst, F.; Oberer, L.; Beerli, C.; Streiff, M.; Pally, C.; Hersperger, R.; Bruns, C.; Bassilana, F.; Bollbuck, B. An oral sphingosine 1 phosphate receptor 1 (S1P1) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation. J. Med. Chem., 2012, 55, 9722-9734.
82. Quancard, J.; Bollbuck, B.; Janser, P.; Angst, D.; Berst, F.; Buehlmayer, P.; Streiff, M.; Beerli, C.; Brinkmann, V.; Guerini, D.; Smith, P. A.; Seabrook, T. J.; Traebert, M.; Seuwen, K.; Hersperger, R.; Bruns, C.; Bassilana, F.; Bigaud, M. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem. Biol., 2012, 19, 1142-1151.
83. Hla, T.; Brinkmann, V. Receptor modulation Physiology and the effects of S1P receptor modulation. Neurology, 2011, 76, S3-S8.
84. Schmouder, R.; Serra, D.; Wang, Y.; Kovarik, J. M.; DiMarco, J.; Hunt, T. L.; Bastien, M. C. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J. Clin. Pharmacol., 2006, 46, 895-904.
85. Murakami, A.; Takasugi, H.; Ohnuma, S.; Koide, Y.; Sakurai, A.; Takeda, S.; Hasegawa, T.; Sasamori, J.; Konno, T.; Hayashi, K.; Watanabe, Y.; Mori, K.; Sato, Y.; Takahashi, A.; Mochizuki, N.; Takakura, N. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol. Pharmacol., 2010, 77, 704-713.
86. Pan, S.; Gray, N. S.; Gao, W.; Mi, Y.; Fan, Y.; Wang, X.; Tuntland, T.; Che, J.; Lefebvre, S.; Chen, Y.; Chu, A.; Hinterding, K.; Gardin, A.; End, P.; Heining, P.; Bruns, C.; Cooke, N. G.; Nuesslein-Hildesheim, B. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med. Chem. Lett., 2013, 4, 333-337.
87. Gergely, P.; Guerini, D.; Brinkmann, V.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J. Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br. J. Pharmacol., 2012, 167, 1035-1047.
88. Aslanis, V.; Faller, T.; Van de Kerkhof, E.; Schubart, A.; Wallstrom, E.; Beyerbach, A. Siponimod (BAF312) (and/or its metabolites) penetrates into the CNS and distributes to white matter areas. 28th Congress of the European Committee for Treatment and Research ans Multiple Sclerosis (ECTRIMS) Oct 2012 10-13, Lyon, France (Poster P792).
89. Fryer, R. M.; Muthukumarana, A.; Harrison, P. C.; Nodop Mazurek, S.; Chen, R. R.; Harrington, K. E.; Dinallo, R. M.; Horan, J. C.; Patnaude, L.; Modis, L. K.; Reinhart, G. A. The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtypespecific Bradycardia (S1P 1) and hypertension (S1P 3) in rat. PLoS One, 2012, 7, 52985-52994.
90. Nuesslein-Hildesheim, B.; Gergely, P.; Wallstrom, E.; Luttringer, O.; Groenewegen, A.; Howard, L.; Pan, S.; Gray, N.; Chen, Y. A.; Bruns, C.; Zecri, F.; Cooke, N. The S1P1/S1P5 receptor modulator BAF312 reverses neurological deficits in ongoing EAE, reduces specific lymphocyte subsets in healthy volunteers and is a potential new multiple sclerosis treatment. 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS); Oct 2009 9-12; Dusseldorf, Germany (Poater P438).
91. Legangneux, E.; Gardin, A.; Johns, D. Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br. J. Clin. Pharmacol., 2013, 75, 831-841.
92. Selmaj, K.; Li, D. K. B.; Hartung, H.; Hemmer, B.; Kappos, L.; Freedman, M. S.; Stuve, O.; Rieckmann, P.; Montalban, X.; Ziemssen, T.; Auberson, L. Z.; Pohlmann, H.; Mercier, F.; Dahlke, F.; Wallstrom, E. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol., 2013, 12, 756-767.
93. Hartung, H.; Pigeolet, E.; Li, D.; Hemmer, B.; Kappos, L.; Freedman, M. S.; Stuve, O.; Rieckmann, P.; Montalban, X.; Ziemssen, T.; Zhang-Auberson, L.; Wallstrom, E.; Selmaj, K. The selective sphingosine 1-phosphate receptor modulator siponimod (BAF312): magnetic resonance imaging lesion and lymphocyte relationship in a phase 2 study in relapsing-remitting multiple sclerosis. 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) Oct 2012 10-13; Lyone, France (Poster P 934).
94. Li, K. B.; Hemmer, B.; Stuve, O.; Hartung, H. P.; Freedman, M. S.; Rieckmann, P.; Montalban, X.; Zhang-Auberson, L.; Pohlmann, H.; Wallstrom, E.; Selmaj, K.; Kappos, L. Siponimod (BAF312) treatment leads to early MRI benefits in relapsing-remitting multiple sclerosis patients: results from a phase 2 study. 28th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) Oct 2012 10-13; Lyone, France; (Poster P494).
95. Hartung, H. P.; Selmaj, K.; Li, D.; Hemmer, B.; Freedman, M.; Stuve, O.; Rieckmann, P.; Montalban, X.; Ziemssen, T.; Zhang-Auberson, L.; Hunter, B.; Rochotte, E.; Wallstrom, E.; Kappos, L. Phase 2 BOLD extension study safety results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Neurology, 2013, 80, (Poster P01. 176).
96. Stuve, O.; Hartung, H. P.; Freedman, M.; Li, D.; Hemmer, B.; Kappos, L.; Rieckmann, P.; Montalban, X.; Ziemssen, T.; Selmaj, K. Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord., 2014, 3, 754-755, (Poster P041).
97. Kappos, L.; Stuve, O.; Hartung, H.; Freedman, M.; Li, D.; Hemmer, B.; Rieckmann, P.; Montalban, X.; Ziemssen, T.; Hunter, B.; Arnould, S.; Wallstrom, E.; Selmaj, K. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: results from dose-blinded extension phase of BOLD study. Neurology, 2014, 82, (Poster P3. 151).
98. A service of the U. S. National Institutes of Health. Exploring the efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis (EXPAND) 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT01665144 (Last accessed January 12, 2015).
99. Kappos, L.; Bar-Or, A.; Cree, B.; Fox, R.; Giovannoni, G.; Gold, R.; Vermersch, P.; Lam, E.; Pohlmann, H.; Zhang-Auberson, L.; Dandekar, A.; Wallstroem, E. Siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis: design of the phase 3 EXPAND trial. Neurology, 2013, 80, (Poster P07. 126).
100. A service of the U. S. National Institutes of Health. Mechanistic Studies of phase III trial with BAF312 in secondary progressive multiple sclerosis 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT02330965 (Last accessed January 12, 2015).
101. Menzin, J.; Caon, C.; Nichols, C.; White, L. A.; Friedman, M.; Pill, M. W. Narrative review of the literature on adherence to diseasemodifying therapies among patients with multiple sclerosis. J. Manag. Care Pharm., 2013, 19, S24-S40.
102. Warnke, C.; Stuve, O.; Kieseier, B. C. Teriflunomide for the treatment of multiple sclerosis. Clin. Neurol. Neurosurg., 2013, 115, S90-S94.
103. Hartung, H. P.; Kieseier, B. C. The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives. Curr. Opin. Neurol., 2014, 27, 243-245.
104. Minen, M. T.; Karceski, S. Multiple sclerosis and diseasemodifying therapies About multiple sclerosis. Neurology, 2011, 77, e26-e27.
105. Plosker, G. L. Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs, 2011, 25, 67-88.
106. Aharoni, R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun. Rev., 2013, 12, 543-553.
107. Boster, A.; Bartoszek, M. P.; O'Connell, C.; Pitt, D.; Racke, M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther. Adv. Neurol. Disord., 2011, 4, 319-332.
108. Fleischer, V.; Salmen, A.; Kollar, S.; Weyer, V.; Siffrin, V.; Chan, A.; Zipp, F.; Luessi, F. Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients. J. Clin. Neurol., 2014, 10, 289-295.
109. Okuda, D. T. Immunosuppressive treatments in multiple sclerosis. Handb. Clin. Neurol., 2014, 122, 503-511.
110. Christophi, G. P.; Christophi, J. A.; Gruber, R. C.; Mihai, C.; Mejico, L. J.; Massa, P. T.; Jubelt, B. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients. J. Neurol. Sci., 2011, 307, 41-45.
111. Hoepner, R.; Faissner, S.; Salmen, A.; Gold, R.; Chan, A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J. Cent. Nerv. Syst. Dis., 2014, 6, 41-49.
112. Ward, M. D.; Jones, D. E.; Goldman, M. D. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin. Drug Saf., 2014, 13, 989-998.
113. R) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol., 2013, 4, 10.
114. R) for the treatment of multiple sclerosis. Exp. Neurol., 2014, 262PA, 57-65.
115. Burness, C. B.; Deeks, E. D. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs, 2014, 28, 373-387.
116. Linker, R.; Gold, R. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr. Neurol. Neurosci. Rep., 2013, 13, 394.
117. Calabresi, P. A.; Kieseier, B. C.; Arnold, D. L.; Balcer, L. J.; Boyko, A.; Pelletier, J.; Liu, S.; Zhu, Y.; Seddighzadeh, A.; Hung, S.; Deykin, A. ADVANCE Study Investigators. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol., 2014, 13, 657-665.
118. Lemtrada Approval History 2015. Available from: URL: http://www. drugs. com/history/lemtrada. html (Last accessed January 12, 2015).
119. A service of the U. S. National Institutes of Health. Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis 2015. Available from: URL: https://clinicaltrials. gov/ct2/show/NCT001 185821 (Last accessed January 12, 2015).